Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTT1R2L)

• DTT Name: Integrin alpha-V (ITGAV) DTT Info
• Gene Name: ITGAV

Molecule-Related Drug & Molecule List

2 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abituzumab	DMTCXSG	Colorectal cancer	2B91.Z	Phase 2	[1]
IMGN-388	DMSYB83	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SB-223245	DM3JQCF	N. A.	N. A.	Terminated	[3]

56 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ac-Asp-Arg-Leu-Asp-Ser-OH	DMYHADT	Discovery agent	N.A.	Investigative	[4]
AcDRGDS	DM9MDBO	Discovery agent	N.A.	Investigative	[5]
C(-GRGDfL-)	DMTMJAI	Discovery agent	N.A.	Investigative	[6]
C(Arg-Gly-Asp-D-Phe-Val)	DMHNZGP	Discovery agent	N.A.	Investigative	[7]
C(RGDfF)	DMMBESU	Discovery agent	N.A.	Investigative	[8]
C(RGDfMeF)	DM8DU42	Discovery agent	N.A.	Investigative	[8]
C-[-Arg-Gly-Asp-Acpca30-]	DML0U8B	Discovery agent	N.A.	Investigative	[9]
C-[-Arg-Gly-Asp-Acpca31-]	DMKENFU	Discovery agent	N.A.	Investigative	[9]
C-[-Arg-Gly-Asp-Acpca32-]	DMVM7B2	Discovery agent	N.A.	Investigative	[9]
C-[-Arg-Gly-Asp-Acpca33-]	DMIBGWO	Discovery agent	N.A.	Investigative	[9]
Cyclo(RGDfV) (control)	DM3QVOB	Discovery agent	N.A.	Investigative	[10]
Cyclo-[-Arg-Gly-Asp-Amp21-]	DMVXPUB	Discovery agent	N.A.	Investigative	[11]
Cyclo-[-Arg-Gly-Asp-Amp22-]	DMBELJK	Discovery agent	N.A.	Investigative	[11]
Cyclo-[-Arg-Gly-Asp-Amp23-]	DMT29VJ	Discovery agent	N.A.	Investigative	[11]
Cyclo-[-Arg-Gly-Asp-Amp24-]	DM35ZLK	Discovery agent	N.A.	Investigative	[11]
Cyclo-[-Arg-Gly-Asp-Amp25-]	DMEIXUQ	Discovery agent	N.A.	Investigative	[11]
Cyclo-[-Arg-Gly-Asp-Amp26-]	DME5HRW	Discovery agent	N.A.	Investigative	[11]
Cyclo-[-Arg-Gly-Asp-Amp27-]	DMBNJZ0	Discovery agent	N.A.	Investigative	[11]
Cyclo-[-Arg-Gly-Asp-Amp28-]	DMJMHAV	Discovery agent	N.A.	Investigative	[11]
CYCLORGDFV	DMGZ0KM	N. A.	N. A.	Investigative	[12]
Cyclo[RGDfK(cypate)]	DMWYFLD	Discovery agent	N.A.	Investigative	[10]
Cypate-[(RGD)2-NH2]1	DMBTU7G	Discovery agent	N.A.	Investigative	[10]
Cypate-[(RGD)2-NH2]2	DMJNW9P	Discovery agent	N.A.	Investigative	[10]
Cypate-[(RGD)3-NH2]1	DMWINK5	Discovery agent	N.A.	Investigative	[10]
Cypate-[(RGD)3-NH2]2	DM1SAIX	Discovery agent	N.A.	Investigative	[10]
Cypate-[(RGD)4-NH2]1	DM3GLMP	Discovery agent	N.A.	Investigative	[10]
Cypate-[(RGD)4-NH2]2	DMR74OM	Discovery agent	N.A.	Investigative	[10]
C[-Arg-Gly-Asp-Acpca19-]	DMPOIDK	Discovery agent	N.A.	Investigative	[9]
C[-Arg-Gly-Asp-Acpca20-]	DMJVW1N	Discovery agent	N.A.	Investigative	[9]
C[-Arg-Gly-Asp-Acpca21-]	DMXCUDV	Discovery agent	N.A.	Investigative	[9]
C[-Arg-Gly-Asp-Acpca22-]	DM6DV90	Discovery agent	N.A.	Investigative	[9]
C[-Arg-Gly-Asp-Acpca34-]	DMKHSAV	Discovery agent	N.A.	Investigative	[9]
C[-Arg-Gly-Asp-Acpca35-]	DMQOY3J	Discovery agent	N.A.	Investigative	[9]
C[-Arg-Gly-Asp-Acpca36-]	DM7LCPW	Discovery agent	N.A.	Investigative	[9]
C[RGD-(R)-alpha-TfmfV]	DMF091Y	Discovery agent	N.A.	Investigative	[8]
C[RGD-(S)-alpha-TfmfV]	DMC9G2Y	Discovery agent	N.A.	Investigative	[8]
C[RGDf-(3R)-Carboxymorpholine]	DM1DMR2	Discovery agent	N.A.	Investigative	[13]
C[RGDf-(3S)-Carboxymorpholine]	DM0ULZM	Discovery agent	N.A.	Investigative	[13]
C[RGDf-(R)-alpha-TfmF]	DMXA0JB	Discovery agent	N.A.	Investigative	[8]
C[RGDf-(R)-alpha-TfmV]	DM8FGMA	Discovery agent	N.A.	Investigative	[8]
C[RGDf-(R)-N-Me-alpha-TfmF]	DM4ZWOD	Discovery agent	N.A.	Investigative	[8]
C[RGDf-(S)-alpha-TfmF]	DMCXJOL	Discovery agent	N.A.	Investigative	[8]
C[RGDf-(S)-alpha-TfmV]	DMLRYXK	Discovery agent	N.A.	Investigative	[8]
C[RGDf-(S)-N-Me-alpha-TfmF]	DMNS3HC	Discovery agent	N.A.	Investigative	[8]
C[RGDf-(S,R)-alpha-Dfm-F]	DMAILK8	Discovery agent	N.A.	Investigative	[8]
E[c(RGDyK)]2	DM76UJY	Discovery agent	N.A.	Investigative	[14]
E[c(RGDyK)]2-PTX conjugate	DMS1LZI	Discovery agent	N.A.	Investigative	[14]
G(D-Pen)-G-H-R-G-D-L-R-C-A	DMUC0F5	Discovery agent	N.A.	Investigative	[15]
Gly-Arg-Gly-Asp-Ser	DMACT8D	Discovery agent	N.A.	Investigative	[16]
Gly-Arg-Gly-Asp-Ser-Pro-Lys	DMGOIME	Discovery agent	N.A.	Investigative	[17]
ISONIPECOTAMIDE	DM5DKUY	Discovery agent	N.A.	Investigative	[18]
N-(3,5-dichlorophenyl)imidodicarbonimidic diamide	DMQ0LF2	Discovery agent	N.A.	Investigative	[19]
NAVPNLRGDLQVLAQKVART	DM3RP25	Discovery agent	N.A.	Investigative	[20]
RGDechi	DMX4JN6	Discovery agent	N.A.	Investigative	[7]
SB-265123	DM8UKH7	Discovery agent	N.A.	Investigative	[21]
ST-1646	DMR1G40	Discovery agent	N.A.	Investigative	[11]

References

• [1] Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015 Jan;26(1):132-40.
• [2] Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 2010 Oct 1;70(19):7591-9.
• [3] Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a resten... Bioorg Med Chem Lett. 1998 Nov 17;8(22):3171-6.
• [4] Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one sc... Bioorg Med Chem. 2007 Dec 1;15(23):7380-90.
• [5] Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2329-33.
• [6] Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81.
• [7] Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem. 2006 Jun 1;49(11):3416-20.
• [8] Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
• [9] Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
• [10] Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
• [11] Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
• [12] Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetr... J Med Chem. 2010 Jan 14;53(1):106-18.
• [13] Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity. Bioorg Med Chem. 2009 Feb 15;17(4):1542-9.
• [14] Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005 Feb 24;48(4):1098-106.
• [15] Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists. J Med Chem. 1994 Jan 7;37(1):1-8.
• [16] alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers. J Med Chem. 2009 Nov 26;52(22):7029-43.
• [17] N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem. 1999 Aug 12;42(16):3033-40.
• [18] Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5227-32.
• [19] Emerging targets in osteoporosis disease modification. J Med Chem. 2010 Jun 10;53(11):4332-53.
• [20] Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands. J Biol Chem. 2007 Mar 30;282(13):9657-65.
• [21] 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5937-41.